Belantamab mafodotin

• UNSPSC Description:

  Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity[1][2].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs)

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/belantamab-mafodotin.html

• Purity:

  99.78

• Solubility:

  10 mM in DMSO

• Smiles:

  [Belantamab mafodotin]

• Molecular Weight:

  149000 (average)

• References & Citations:

  [1]Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.|[2]Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C, protect from light

• Clinical Information:

  Launched

• CAS Number:

  2050232-20-5